课题基金 / 基金详情

StAtins for Venous Event Reduction in patients with venous thromboembolism (The SAVER Trial)

StAtins for Venous Event Reduction in patients with venous thromboembolism (The SAVER Trial)
他汀类药物可减少静脉血栓栓塞患者的静脉事件（SAVER 试验）
批准号：
401772
负责人：
Delluc Aurelien
金额：
$252.09万
依托单位：
Ottawa Hospital Research Institute
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-03-01 至 2024-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=401772&lang=en
关键词：
Adjuvent Arterial Vascular Events Deep Vein Thrombosis Post-Thrombotic Syndrome Pulmonary Embolism Randomized Controlled Trial Rosuvastatin Secondary Prevention Statin Venous Thromboembolism

项目摘要

项目成果

Delluc Aurelien的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Rosuvastatin belongs to a family of drugs called statins. They are prescribed for patients with elevated cholesterol levels and have been found to decrease the incidence of arterial events such as heart attack and stroke. It is possible that statins may a
期刊论文(0)
专著(0)
科研奖励(0)
会议论文